Considering the aforementioned mechanism, targeted UBR5 significantly inhibits tumor growth, eliminates the ability of ovarian cancer to resist conventional chemotherapy and immunotherapy, and significantly improves the effect of the standard treatment of ovarian cancer. Here, UBR5 is linked to ovarian carcinoma.